Enter inventor name

Jorgen Drejer

This inventor holds 28 USPTO granted patents, plus 1 CIPO patent, primarily in Pharmaceutical Chemistry. Top assignees: Neurosearch A/s, Novo Nordisk A/s, A/s Ferrosan. Active years: 1989-2004.

USPTO Granted Patents = 28

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 5)

Average Co-Inventor Count = 2.5

ph-index = 7

Forward Citations = 144(Granted Patents)

Location History:

Bronshoj, DK (1989 - 1991)
V rlose, DK (1992 - 1995)
Vaerlose, DK (1990 - 2001)
Ballerup, DK (2001)
Glostrup, DK (2000 - 2004)

Company Filing History:

Years Active: 1989-2004

Loading Chart...

Areas of Expertise:

Indole Derivatives

AMPA Antagonists

Neurotrophic Activity

Piperidine Compounds

Calcium Overload

Isatineoxime Derivatives

Aryloxyphenylpropylamines

Fused Compounds

Tricyclic Heterocycles

Pharmaceutical Compositions

Therapeutic Use

Excitatory Amino Acids

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6693111 - Indole-2,3-dione-3-oxime derivatives (2004-02-17),

2. 6239128 - Indole-2,3-dione-3-oxime derivatives for therapeutic use (2001-05-29),

3. 6180649 - 1-(4-piperidyl)-benzimidazoles having neurotrophic activity (2001-01-30),

4. 6124285 - Indole-2,3-dione-3-oxime derivatives (2000-09-26),

5. 5843945 - AMPA antagonists and a method of treatment (1998-12-01),

6. 5780493 - AMPA antagonists and method of treatment therewith (1998-07-14),

7. 5478859 - Indole-derivatives, method of treatment therewith, and pharmaceutical (1995-12-26),

8. 5436250 - Isatineoxime derivatives, their preparation and use (1995-07-25),

9. 5310756 - Aryloxyphenylpropylamines and their calcium overload blocking (1994-05-10),

10. 5270306 - Method of antagonizing excitatory amino acids by administration of (1993-12-14),

11. 5242918 - Isatinoxime derivatives, their preparation and use (1993-09-07),

12. 5227379 - Piperidine compounds and their preparation and use (1993-07-13),

13. 5223527 - Isatineoxime derivatives and their use (1993-06-29),

14. 5198461 - Isatine derivatives, their preparation and use (1993-03-30),

15. 5158961 - Piperidine compounds and their preparation and use (1992-10-27),

Title: Jorgen Drejer: A Pioneering Innovator in Therapeutic Applications

Introduction

Jorgen Drejer is a prominent inventor based in Vaerlose, Denmark, known for his significant contributions to the field of therapeutics. With a remarkable portfolio consisting of 28 patents, Drejer has made a substantial impact through his innovative work aimed at combating various diseases and disorders.

Latest Patents

Among his latest patents are the indole-2,3-dione-3-oxime derivatives and their therapeutic applications. These inventions focus on utilizing indole-2,3-dione-3-oxime derivatives in methods intended to combat diseases associated with the release of excitatory amino acids. This research reflects his commitment to developing novel treatments that can address critical health challenges.

Career Highlights

Throughout his career, Jorgen Drejer has worked with several esteemed companies, including Neurosearch A/S and Novo Nordisk A/S. His experiences in these organizations have provided him with a strong foundation for his innovative endeavors. Drejer's work has not only advanced scientific understanding but also contributed to the development of new therapeutic options.

Collaborations

Drejer has collaborated with notable colleagues, such as Frank Watjen and Palle Jakobsen. These partnerships have enriched his research efforts and fostered a collaborative environment that encourages innovation and creativity in therapeutic development.

Conclusion

Jorgen Drejer stands out as a dedicated inventor whose contributions are paving the way for new therapeutic treatments. His 28 patents are a testament to his inventive spirit and commitment to improving health outcomes. As he continues his work in this field, the potential for further innovations remains promising, highlighting the importance of ongoing research and development in medicine.

Profile summary based on public USPTO records.

Please report any incorrect information to [email protected]